AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.
You may also be interested in...
Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
AstraZeneca To Cut 3,000 Jobs As It Seeks To Rationalize Production Assets
CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.